

Major R&D Pipeline: 3ADCs

As of Oct 2021





	Phase 1	Phase 2	Phase 3	Submitted
(JP/US) NSCLC, TNBC, HR+ BC TROPION-PanTumor01	(US/EU/Asia) HER2+ BC 2L~/1L DESTINY-Breast07	(US/EU/Asia) TNBC (durvalumab combo) BEGONIA	(JP/US/EU/Asia)HER2+ BC 3L DESTINY-Breast02	
(JP/US/EU/Asia) NSCLC (w/o actionable mutation, pembrolizumab combo) TROPION-Lung02	(US/EU/Asia) HER2 low BC chemo naïve/ post chemo DESTINY-Breast08	(US/EU) HER2+ GC 2L DESTINY-Gastric02	(JP/US/EU/Asia) HER2+ BC 2L DESTINY-Breast03	
(JP/US/EU/Asia) NSCLC (w/o actionable mutation, durvalumab combo) TROPION-Lung04	(US/EU/Asia) HER2+ GC combo, 2L~/1L DESTINY-Gastric03	(China) HER2+ GC 3L DESTINY-Gastric06	(JP/US/EU/Asia) HER2 low BC post chemo DESTINY-Breast04	
(US/EU/Asia) TNBC (durvalumab combo) BEGONIA	(EU/Asia)HER2+ NSCLC (durvalumab combo) 1L DESTINY-Lung03	(JP/US/EU)HER2+/mutated NSCLC 2L~ DESTINY-Lung01	(JP/US/EU/Asia) HER2+ BC post neoadjuvant DESTINY-Breast05	
(JP/US/EU/Asia) NSCLC	(US/EU) BC, bladder (nivolumab combo)	(JP/US/EU/Asia) HER2 mutated NSCLC 2L~ DESTINY-Lung02	(JP/US/EU/Asia) HER2 low BC chemo naïve DESTINY-Breast06	
(JP/US)EGFR mutated NSCLC (osimertinib combo)	(US/EU) BC, NSCLC (pembrolizumab combo)	(US/EU/Asia) NSCLC (durvalumab combo) 2L~ HUDSON	(US)HER2+ BC 1L DESTINY-Breast09	
(JP/US) BC		(JP/US/EU) HER2+ CRC 3L DESTINY-CRC01	(JP/EU/Asia) HER2+ GC 2L DESTINY-Gastric04	
		(JP/US/EU/Asia) HER2+ CRC 3L DESTINY-CRC02	(US/EU/Asia) NSCLC (w/ exon 19 or exon 20 mutation) DESTINY-Lung04	
		(US/EU/Asia) HER2 mutated tumor DESTINY-PanTumor01	(JP/US/EU/Asia) NSCLC (w/o actionable mutation) TROPION-Lung01	
		(US/EU/Asia) HER2 expressing tumor DESTINY-PanTumor02		
		(JP/US/EU/Asia) NSCLC (w/ actionable mutation) TROPION-Lung05		
		(JP/US/EU/Asia) EGFR mutated NSCLC HERTHENA-Lung01		
		(JP/US/EU) CRC 3L		




- ENHERTU®
- Dato-DXd
- HER3-DXd

BC: breast cancer, CRC: colorectal cancer, GC: gastric cancer, NSCLC: non-small cell lung cancer, TNBC: triple negative breast cancer
 : project in oncology that is planned to be submitted for approval based on the results of phase 2 trials
 : Breakthrough Designation (US)




Major R&D Pipeline: Alpha

As of Oct 2021

Phase 1		Phase 2	Phase 3	Submitted
DS-7300 (JP/US) B7-H3-directed ADC ESCC, CRPC, SCLC, etc.	DS-3201 (JP/US) EZH1/2 inhibitor Non-Hodgkin's lymphomas	DS-3201 (JP) EZH1/2 inhibitor ATL/L	Quizartinib (JP/US/EU/Asia) FLT3 inhibitor 1L AML 	Mirogabalin (JP) $\alpha\delta$ Ligands Central neuropathic pain
DS-6000 (US) CDH6-directed ADC Renal cell carcinoma, ovarian cancer	PLX2853 (US) BET inhibitor AML	DS-3201 (JP/US/EU/Asia) EZH1/2 inhibitor PTCL 	Pexidartinib (JP/Asia) CSF-1/KIT/FLT3 inhibitor Tenosynovial giant cell tumor	Prasugrel (JP) ADP receptor inhibitor Ischemic stroke
DS-1055 (JP/US) Anti-GARP antibody Solid tumors	PLX2853 (US) BET inhibitor Solid tumor	DS-1001 (JP) Mutant IDH1 inhibitor Glioma	Esaxerenone (JP) MR blocker Diabetic nephropathy	VN-0107/MEDI3250 (JP) Live attenuated influenza vaccine nasal spray
DS-1211 (US) TNAP inhibitor Pseudoxanthoma elasticum 	PLX2853 (US) BET inhibitor Gynecologic neoplasms, ovarian cancer	DS-5141 (JP) ENA oligonucleotide DMD 	VN-0102/JVC-001 (JP) Measles mumps rubella combined vaccine	
DS-6016 (JP) Anti-ALK2 antibody Fibrodysplasia Ossificans Progressiva	PLX2853 (US) BET inhibitor Prostate cancer			
DS-5670 (JP) mRNA vaccine COVID-19	DS-1594 (US) Menin-MLL binding inhibitor AML, ALL			
	VN-0200 (JP) RS virus vaccine RS virus			

-  Oncology
-  Specialty medicine
-  Vaccine

AF: atrial fibrillation, ALL: acute lymphoblastic leukemia, AML: acute myeloid leukemia, ATL/L: adult T-cell leukemia/lymphoma, CRPC: castration-resistant prostate cancer, DMD: Duchenne muscular dystrophy, ESCC: esophageal squamous cell carcinoma, GIST: gastrointestinal stromal tumor, SCLC: small cell lung cancer, PTCL: peripheral T-cell lymphoma

: project in oncology that is planned to be submitted for approval based on the results of phase 2 trials : SAKIGAKE Designation (JP) : Orphan drug designation (JP/US/Europe)